Skip to main content

Compass Therapeutics, Inc 10-Q for FY2026 Q3

Compass Therapeutics, Inc. (CMPX)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Compass Therapeutics, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Compass Therapeutics held $163 million in cash, cash equivalents and marketable securities as of September 30, 2026 and expects those resources to fund operating expenses and capital expenditure requirements into 2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$27.17M
compared with a net loss of $14.26M a year earlier